| Morphiceptin | |
|---|---|
|
(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]-N-[(2S)-1-[(2S)-2-carbamoylpyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]pyrrolidine-2-carboxamide[1] |
|
|
Other names
Tyr-Pro-Phe-Pro-NH2, PLO17 |
|
| Identifiers | |
| CAS number | 87777-29-5 |
| PubChem | 119303 |
| ChemSpider | 3754959 |
| Jmol-3D images | Image 1 |
|
|
| Properties | |
| Molecular formula | C28H35N5O5 |
| Molar mass | 521.6 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) |
|
| Infobox references | |
Morphiceptin is a tetrapeptide (Tyr-Pro-Phe-Pro-NH2) that is a selective μ-opioid receptor agonist. It is derived from β-casomorphin and has over 1,000 times selectivity for μ- over δ-opioid receptors. When administered intracerebroventricularly, morphiceptin had an analgesic ED50 of 1.7 nmol per animal. The analgesic effects of morphiceptin were reversed by naloxone, meaning that the analgesic effect is mediated by the μ-opioid receptor.[2]
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)